Measurement of Human Intercellular Adhesion Molecule 1 in the Blood Is Useful for Predicting the Occurrence of Hepatocellular Carcinomas from Chronic Hepatitis C and Liver Cirrhosis

Moriyama, Mitsuhiko; Matsumura, Hiroshi; Shioda, Jiro; Aoki, Hiroshi; Nakamura, Hitomi; Arakawa, Yasuo; Nirei, Kazushige; Yanagimoto, Hiroaki; Kushima, Miki; Tanaka, Naohide; Arakawa, Yasuyuki

doi:10.1159/000095152

Cited by 10 publications

(7 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plasma levels of sICAM-1 have been reported to be associated with liver disease activity, HCC occurrence and prognosis [17], [20], [21], [22]. There is growing evidence that the ABO blood group is highly significantly associated with variation in the levels of a number of biomarkers.…”

Section: Discussionmentioning

confidence: 99%

“…Single nucleotide polymorphisms (SNPs) at the ABO locus were associated with two serum markers of inflammation: TNF-α and soluble intercellular adhesion molecule 1 (sICAM-1) [14], [15]. Enhanced expression of TNF-α is associated with liver inflammation and hepatocarcinogenesis[16], also plasma levels of sICAM-1 are not only associated with the risk of incident diabetes and liver disease activity, known predisposing factors for HCC, but furthermore are also a predictive marker of HCC occurrence and prognosis [17], [18], [19], [20], [21], [22]. These indicate a possible link between the ABO blood group and HCC risk, especially in the presence of other etiological risks for HCC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

ABO Blood Group and the Risk of Hepatocellular Carcinoma: A Case-Control Study in Patients with Chronic Hepatitis B

Jin-hong

et al. 2012

PLoS ONE

View full text Add to dashboard Cite

BackgroundStudies have observed an association between the ABO blood group and risk of certain malignancies. However, no studies of the association with hepatocellular carcinoma (HCC) risk are available. We conducted this hospital-based case-control study to examine the association with HCC in patients with chronic hepatitis B (CHB).MethodsFrom January 2004 to December 2008, a total of 6275 consecutive eligible patients with chronic hepatitis B virus (HBV) infection were recruited. 1105 of them were patients with HBV-related HCC and 5,170 patients were CHB without HCC. Multivariate logistic regression models were used to investigate the association between the ABO blood group and HCC risk.ResultsCompared with subjects with blood type O, the adjusted odds ratio (AOR) for the association of those with blood type A and HCC risk was 1.39 [95% confidence interval (CI), 1.05–1.83] after adjusting for age, sex, type 2 diabetes, cirrhosis, hepatitis B e antigen, and HBV DNA. The associations were only statistically significant [AOR (95%CI) = 1.56(1.14–2.13)] for men, for being hepatitis B e antigen positive [AOR (95%CI) = 4.92(2.83–8.57)], for those with cirrhosis [AOR (95%CI), 1.57(1.12–2.20)], and for those with HBV DNA≤105copies/mL [AOR (95%CI), 1.58(1.04–2.42)]. Stratified analysis by sex indicated that compared with those with blood type O, those with blood type B also had a significantly high risk of HCC among men, whereas, those with blood type AB or B had a low risk of HCC among women.ConclusionsThe ABO blood type was associated with the risk of HCC in Chinese patients with CHB. The association was gender-related.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

ABO Blood Group and the Risk of Hepatocellular Carcinoma: A Case-Control Study in Patients with Chronic Hepatitis B

Jin-hong

et al. 2012

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Interestingly, we found that many inflammatory/immune-related genes in the 41 gene-classifier were overexpressed in þ357 GGþGC group, including intercellular adhesion molecule (ICAM)-1, ICAM-2, chemokine (C-X-C motif) ligand 1 (CXCL-1, GRO-a), tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B), PACAP-responsive gene 1 (PRG1), and adhesion molecule with Ig-like domain 2 (AMIGO2). More interestingly, overexpression of many genes in the 41-gene classifier such as ICAM-1 (35,36), CXCL1 (GRO-a; 37), SOD2 (38) in HCC metastasis or a decreased OS. These findings indicate that tagSNP þ357 GGþGC genotypes of HTPAP may produce molecular signatures of metastasis, particularly involving genes associated with inflammatory/immune responses.…”

Section: Discussionmentioning

confidence: 99%

Association of Specific Genotypes in Metastatic Suppressor HTPAP with Tumor Metastasis and Clinical Prognosis in Hepatocellular Carcinoma

Ren

Dong

et al. 2011

Cancer Research

View full text Add to dashboard Cite

The phosphatidic acid phosphatase HTPAP has been defined as a metastatic suppressor of hepatocellular carcinoma (HCC), but little is known about its function or potential applications as a prognostic marker. In this study, we analyzed patterns of HTPAP genetic variation and gene expression in 864 patients who underwent HCC resection, assessing these patterns for correlations to tumor metastasis potential. Focusing on two tagSNPs that were selected (þ357G/C and þ1838A/G), we found that only the þ357G/C genotype was significantly associated with HTPAP mRNA and protein expression levels and the probability of metastasis. In an independent cohort of 665 HCC patients, we determined that the þ357G/C genotype was associated with shorter time to recurrence and overall survival. Together, these results indicated that the HTPAP tagSNP þ357 GGþGC genotypes may influence HCC metastatic potential and clinical prognosis by down-regulating HTPAP expression. Extending these results, a global expression profiling analysis identified 41 genes including the proinflammatory genes IL-8 and TLR2 that were significantly overexpressed in the þ357 GGþGC group, as possible coregulated markers with HTPAP. Together, our findings identify an HTPAP genotype and associated gene expression pattern that favors metastasis progression and that could be used to predict tumor metastasis and prognosis in HCC patients. Cancer Res; 71(9); 3278-86. Ó2011 AACR.

show abstract

“…Whilst soluble form of ICAM-1 (sICAM-1) is partly detectable in the serum of healthy subjects, its level increases in malignancies. sICAM-1 serum level is associated with tumor size, lymph node and distant metastasis of cancers, including breast cancer, pancreatic cancer, gastric cancer, lung cancer and hepatocellular carcinoma (Nakata et al, 2000;Felding-Habermann et al, 2001;Alexiou et al, 2003;Moriyama et al, 2006;Gogali et al, 2010;Brand et al, 2011;Eggeman et al, 2011). Gliomas call for disruption of endothelial cell-cell attachment and cell-matrix adhesion, cell migration, and formation of new cell-cell interactions.…”

Section: Introductionmentioning

confidence: 99%

Investigation of ICAM-1 and β3 Integrin Gene Variations in Patients with Brain Tumors

Yılmaz

Zeybek²,

Kahraman³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Primary brain tumors constitute a small percent of all malignant cancers, but their etiology remains poorly understood. β3 integrin (ITGB3) has been recognized to play influential roles in angiogenesis, tumor growth and metastasis. Intercellular adhesion molecule-1 (ICAM-1) is a surface glycoprotein important for tumor invasion and angiogenesis. The aim of this study was to investigate whether specific genetic polymorphisms of ICAM-1 and ITGB3 could be associated with brain cancer development and progression in a Turkish population. Our study is the first to our knowledge to investigate the relationship between brain tumor risk and ICAM-1 and β3 integrin gene polymorphisms. Materials and Methods: The study covered 92 patients with primary brain tumors and 92 age-matched healthy control subjects. Evaluation of β3 integrin (Leu33Pro (rs5918)) and ICAM-1 (R241G (rs1799969) and K469E (rs5498)) gene polymorphisms was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Results: According to results of our research, the A allele of the ICAM-1 R241G gene polymorphism appeared to be a risk factor for primary brain tumors (p<0.001). Similarly, the frequency of the A mutant allele of ICAM-1 R241G was statistically significant in patients with brain tumors classified as glioma (p<0.001). When allele and genotype distributions of ICAM-1 K469E, ICAM-1 R241G and β3 integrin Leu33Pro gene polymorphisms were evaluated with age, sex, and smoking, there were no statistically significant differences. Haplotype analysis revealed that the frequencies of GAC (rs1799969-rs5498-rs5918) and GAT (rs1799969-rs5498-rs5918) haplotypes were significantly lower in patients as compared with controls (p=0.001; p=0.036 respectively). Conclusions: This study provides the first evidence that ICAM-1 R241G SNP significantly contributes to the risk of primary brain tumors in a Turkish population. In addition, our results suggest that ICAM-1 R241G in combination ICAM-1 K469E may have protective effects against the development of brain cancer.

show abstract

Measurement of Human Intercellular Adhesion Molecule 1 in the Blood Is Useful for Predicting the Occurrence of Hepatocellular Carcinomas from Chronic Hepatitis C and Liver Cirrhosis

Cited by 10 publications

References 32 publications

ABO Blood Group and the Risk of Hepatocellular Carcinoma: A Case-Control Study in Patients with Chronic Hepatitis B

ABO Blood Group and the Risk of Hepatocellular Carcinoma: A Case-Control Study in Patients with Chronic Hepatitis B

Association of Specific Genotypes in Metastatic Suppressor HTPAP with Tumor Metastasis and Clinical Prognosis in Hepatocellular Carcinoma

Investigation of ICAM-1 and β3 Integrin Gene Variations in Patients with Brain Tumors

Contact Info

Product

Resources

About